FDA-483 Response Article and Submission Review Tool

“Your Response Is Inadequate” — FDA-483 Response Article and Submission Review Tool

Before you submit your FDA-483 response, can you support the conclusions it contains?

A response can promise revised procedures, employee retraining, and corrective actions while leaving FDA’s most consequential concerns unanswered. How widespread is the failure? Could distributed products be affected? Why did Quality approve the original decisions, and what evidence demonstrates that the corrective actions will work?

Developed by DeVaughn Edwards, former FDA Investigator and pharmaceutical executive, this package combines practical analysis with an editable assessment tool to help your team identify those gaps before management signs the response.

What’s included

PDF article — “‘Your Response Is Inadequate’: Why Your FDA-483 Response May Still Lead to a Warning Letter”

Drawing on an FDA Warning Letter, the article explains why remediation commitments may fail to address the underlying findings. A fictional example compares a weak response with a more defensible version, showing how to address retrospective-review scope, distributed-product impact, interim controls, Quality Unit oversight, supporting evidence, and corrective-action effectiveness.

Editable Word tool — FDA-483 Response Submission Review Worksheet

Use this structured assessment to challenge a draft response and document unsupported conclusions, missing evidence, and unresolved commitments. Record supporting references and assign actions, responsible owners, and completion dates. The tool also prompts reviewers to examine contradictions between the company’s conclusions and supplier statements, trends, or other records.

Who this is for

Pharmaceutical Quality Assurance, Regulatory Affairs, manufacturing leadership, consultants, and personnel responsible for investigations, CAPAs, and FDA inspection responses.

Use the package to review an active response, train your response team, or assess readiness before an inspection.

Includes one PDF article and one editable Microsoft Word assessment tool.

These resources focus on drug CGMP inspection responses. They support informed review and do not guarantee FDA acceptance or prevention of a Warning Letter.

Included at no additional charge for paid FDA Lens members on Substack.